Rebecca Attwood

Page 2

Research from the University of Southampton, involving scientists at the Centre for Cancer Immunology, could pave the way for new treatments for chronic lymphocytic leukaemia (CLL), giving fresh hope for patients. CLL is the most common type of adult leukaemia and patients who relapse on current therapies have a poor survival outlook. In patients with CLL, the lymph nodes are known to be the critical tissue site for tumour cell survival and growth. Continue reading →

Research from the University of Southampton, involving scientists at the Centre for Cancer Immunology, could pave the way for new treatments for chronic lymphocytic leukaemia (CLL), giving fresh hope for patients. CLL is the most common type of adult leukaemia and patients who relapse on current therapies have a poor survival outlook. In patients with CLL, the lymph nodes are known to be the critical tissue site for tumour cell survival and growth. Continue reading →

Scientists at the University of Southampton’s Centre for Cancer Immunology together with colleagues in the School for Biological Sciences have shed new light on a key aspect of the immune system. It is known that many therapeutic antibodies targeting cancer work by recruiting the immune system. However, the body has a large number of other antibodies in circulation and within tissues that can act as competition for binding to the immune cell receptors that bind antibodies. Continue reading →

Cancer immunotherapy research in Southampton has been given a boost thanks to new funding by Cancer Research UK. Immunotherapy treatments using antibodies have become very successful over the past few years and are now used to treat multiple cancers. However, despite this success, many patients still fail to respond or relapse after treatment. Scientists at the Centre for Cancer Immunology, the UK’s first centre dedicated to cancer immunology research, have been awarded £2. Continue reading →

Cancer immunotherapy research in Southampton has been given a boost thanks to new funding by Cancer Research UK. Immunotherapy treatments using antibodies have become very successful over the past few years and are now used to treat multiple cancers. However, despite this success, many patients still fail to respond or relapse after treatment. Scientists at the Centre for Cancer Immunology, the UK’s first centre dedicated to cancer immunology research, have been awarded £2. Continue reading →

Professor Mark Cragg from the Centre for Cancer Immunology is part of a review of recent discoveries on how antibodies work in our bodies. Continue reading →

A scientist at the Centre for Cancer Immunology has been involved in a study that shows, for the first time, the real-world vaccine responses and infection outcomes in clinically at-risk patients with a range of immunocompromised or immunosuppressed conditions. Continue reading →

Clinician scientists based at the Centre for Cancer Immunology have shown a rare form of cancer can be treated with a drug that’s already available on the NHS. Hairy Cell Leukaemia (HCL) is a chronic leukaemia and gets its name from the tiny, hair-like projections on the cell’s surface. Current treatment is usually chemotherapy which has many side effects and does not eradicate the disease completely. Continue reading →

Clinician scientists based at the Centre for Cancer Immunology have shown a rare form of cancer can be treated with a drug that’s already available on the NHS. Hairy Cell Leukaemia (HCL) is a chronic leukaemia and gets its name from the tiny, hair-like projections on the cell’s surface. Current treatment is usually chemotherapy which has many side effects and does not eradicate the disease completely. Continue reading →